University of California San Francisco

Robert J. Ignoffo, PharmD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ignoffo_robert

Clinical Professor, Department of Clinical Pharmacy, UCSF

ignoffob@pharmacy.ucsf.edu

Phone: (415) 476-1230 (voice)
Box 0622, UCSF
San Francisco, CA 94143-0622


Education

San Francisco State University, Bachelor of Arts, 1962-67, Chemistry, San Francisco, California
University of California, San Francisco, School of Pharmacy, 1967-71, Doctor of Pharmacy (Pharm.D.), San Francisco, California
University of California, San Francisco, School of Pharmacy, 1971-72, Resident in Pharmacy, San Francisco, California

Professional Experience

  • 1972-79
    Assistant Clinical Professor, University of California, San Francisco, School of Pharmacy, San Francisco, California
  • 1973-74
    Assistant Director, Continuing Education in Pharmacy,University of California, San Francisco, School of Pharmacy, San Francisco, California
  • 1980-86
    Associate Clinical Professor, University of California, San Francisco, School of Pharmacy, San Francisco, California
  • 1986 -present
    Clinical Professor, University of California, San Francisco, School of Pharmacy, San Francisco, California Division of Clinical Pharmacy and Division of Oncology, School of Medicine
  • 1993, 94, 96, 98, 2000
    Director, Oncology Pharmacy Residency
  • 1995
    Oncology Team Co-coodinator
  • 2000-present
    Co-Director Pharmacy Residency Programs, Director, Pharmacy Specialty Program

Honors & Awards

  • 1983
    Excellence in Residency Preceptorship, UCSF Pharmacy Residents
  • 1992
    Fellow of the American Society of Health-System Pharmacists
  • 1992
    American Cancer Society (San Francisco Unit) Award for Contributions to the Prevention of Lung Cancer in San Francisco
  • 1995
    Fellow of the California Society of Health-System Pharmacists

Selected Publications

  • Journal Articles
  • Glaucoma. T.G. Tong and R.J. Ignoffo. J. Am. Pharm. Assoc. NS12, 520-534 (1972). Incidence of Bleeding Complications in Patients on Intermittent IV Heparin Therapy. R.J. Ignoffo. Drug Intell. Clin. Pharm. 9, 560-565 (October 1975).
  • Adriamycin-Cyclophosphamide Treatment of Squamous Cell Carcinoma of the Cervix. D.S. Alberts and R.J. Ignoffo. Cancer Treat. Rep. 62 (1978).
  • Therapy of Local Toxicities Caused by Extravasation of Cancer Chemotherapeutic Drugs. R.J. Ignoffo, and M.A. Friedman. Cancer Treat. Rev. 7, 17-27 (1980).
  • A Review of the United States Experience of the Fluoro-Pyrimidine, Ftorafur (NSC-148958). M.A. Friedman and R.J. Ignoffo. Cancer Treat. Rev. 7 (1980).
  • Pain Management of the Cancer Patient. R.J. Ignoffo. Front. Radiat. Ther. Onc. 15, 130-137 (1981).
  • Pharmacokinetics of Methotrexate Administered via the Hepatic Artery. R.J. Ignoffo, S. Øie and M.A. Friedman. Cancer Chemother. Pharmacol. 5, 217-220 (1981).
  • Handling of Cytotoxic Drugs. D. Honda, R.J. Ignoffo and L. Power. CSHP Voice (1981).
  • Adjusting Heparin Infusion Rates from the Initial Response to Activated Coagulation Time. P.J. Hattersley, J.C. Mitsuoka, R.J. Ignoffo, et al. Drug Intel. Clin. Pharm. 17, 632 (1983).
  • Phase I Trial of the Sensitizer Misonidazole with Intravenous Melphalan. C.N. Coleman, M.A. Friedman, R.J. Ignoffo, et al. Cancer Res. 43, 5022-5025 (1983).
  • Phase II Study of Sequential Methotrexate 5-FU Plus Mitomycin C and Leucovorin in Patients with Disseminated Large Bowel Cancer: A Northern California Oncology Group Study. R.J. Ignoffo, M.A. Friedman, M. Gribble, and J. Hannigan. Cancer Treat. Rep. 68, 983-988 (1984).
  • Hepatic Arterial Chemotherapy in the Management of Colorectal Cancer Metastatic to the Liver A Review. R.J. Stagg, B.J. Lewis, R.J. Ignoffo, M.A. Friedman, and D.C. Hohn. Ann. Int. Med. 100, 736-743 (1984).
  • Intravenous Antibiotics, Avoiding Complications. R.A. Smith, V.G. Pons and R.J. Ignoffo. J. Oral Surg. 39, 22-32 (1984).
  • Biliary Sclerosis in Patients Receiving Hepatic Arterial Infusions of Floxuridine. D. Hohn,, J. Melnick, R. Staff, D. Altman, M. Friedman, R.J. Ignoffo, et al. J. Clin. Oncol. 3, 98-102 (1985).
  • Sequential Infusions of Methotrexate and 5-Fluorouracil in Advanced Cancer: Pharmacology, Toxicity, and Response. C. Benz, M. DeGregorio, S. Saks, N. Sambol, W. Holleran, R. Ignoffo, B. Lewis, and E. Cadman. Cancer Res. 45, 3354-3358 (1985).
  • Toxicities and Complications of Implanted Pump Hepatic Arterial and Intravenous Floxuridine Infusion. D.C. Hohn, A.A. Rayner, J.S. Economou, R.J. Ignoffo, et al. Cancer 57, 465-470 (1986).
  • Randomized Trial of Continuous Intravenous versus Hepatic Inta-Arterial Floxuridine in Patients with Colorectal Cancer Metastatic to Liver: the NCOG Trial. D.C. Hohn, R.D. Stagg, M.A. Friedman, J.F. Hannigan, A. Raynor, R.J. Ignoffo, P. Acord, and B.J. Lewis. J. Clin. Oncol. 7, 1646 (1989).
  • Drug Interaction with Erythromycin and Cyclosporin. R.J. Ignoffo and L.E. Kim. Drug Intell. Clin. Pharm. 25, 30-31 (1991).
  • Parenteral Nutrition Support in Patients with the Cancer Patient. Pharmacotherapy (1992; 12:353-357).
  • Pharmaceutical Care and the Cancer Patient. Journal of Oncology Pharmacy Practice; (1995; 1:7-19.
  • The role of the oncology clinical pharmacist in Managed Care? RJ Ignoffo and R Shane. Pharmacy Practice Management Quarterly 1996; 16:50-58.
  • Review of Liposomal Doxorubicin. Kenneth Linsky and RJ Ignoffo. Cancer Practice 1996;4:288290.
  • Docetaxel in Breast Cancer. Yuk Fung Hui and Robert J Ignoffo. Cancer Practice 15:124,1997.
  • Gemcitabine for the Treatment of Pancreatic Cancer. Yuk Fung Hui and Robert J Ignoffo. Hospital Pharmacy 1997;32:1510-1517
  • Dodd, MJ; Larson, PJ; Dibble, SL; Miaskowski, C; Greenspan, D; MacPhail, L; Hauck, WW; Paul, SM; Ignoffo, R; Shiba,G. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncology Nursing Forum, 1996 Jul, 23(6):921-7.
  • The Pro-self Mouthcare Aware Program: An Effective Approach for Reducing Chemotherapy-induced Mucositis. P. Larsen, C Miaskowski, L MacPhail, D Greenspan, MJ Dodd, S Dibble, SM Paul, RJ Ignoffo. Cancer Nursing, 1998 Aug, 21(4):263-8.
  • An Overview of Cancer in the Elderly.A focus on Pharmacotherapy, Part 1. RJ Ignoffo U.S. Pharmacist 2001 September (in press).
  • An Overview of Cancer in the Elderly.A focus on Pharmacotherapy, Part 2. RJ Ignoffo U.S. Pharmacist 2001 October (in press).
  • The Role of Chemoprotectans in Cancer Supportive Care. MS Lam & RJ Ignoffo. Oncology Spectrums vol 2, September 2001
  • Books
  • Manual of Oncology Therapeutics. K. See-Lasley and R.J. Ignoffo. St. Louis: C.V. Mosby Co., 1981.
  • Cancer Chemotherapy Protocols: Drug Administration Guidelines. R. Ignoffo and P. Forni. San Francisco and Emeryville: Vicom Co. and Cetus Corp., 1989.
  • Cancer Chemotherapy Protocols: Drug Administration Guidelines, Revised by Robert Dorr, R. Ignoffo and P. Forni, and . San Francisco and Emeryville: Vicom Co. and Cetus Corp., 1992.
  • Pocketguide on Cancer Chemotherapy (R Ignoffo, C Viele, A Venook, and L Damon, eds) Lippincott-Raven (December, 1997)
  • Abstracts
  • The Pharmacology of Moderate Dose Methotrexate (MTX) Administered via the Hepatic Artery. R.J. Ignoffo and M.A. Friedman. Am. Assoc. Cancer Res. Abstracts 20, No. 19 (1979).
  • Combination 5FU + Moderate Dose Methotrexate (MTX) + Leukovorin (L) - Phase I - II Study for Patients with Disseminated Colorectal Cancer. M.A. Friedman, R.J. Ignoffo, and J.J. Resser. Am. Soc. Clin. Oncol., Abstracts 20, C-61 (March 1979).
  • A Model for Skin Toxicity of Antineoplastic Drugs. R.J. Ignoffo, E. Rubinstein, W. Tomlin and M.A. Friedman. Clin. Res., Abstract (April 1981).
  • How Important is Route of Administration? A Randomized Comparison of Intra-Arterial and Intravenous Floxuridine (Fudr) For Patients with Colorectal Cancer Metastatic to Liver. M.A. Friedman, R.J. Stagg, R.J. Ignoffo, C. Viele, K.J. Resser, and D.C. Hohn. Proc. Amer. Soc. Clin. Oncol. 2, 129 (Abstract C-503) (1983).
  • Sequential Methotrexate-5Fu Plus Mitomycin C and Leucovorin in Patients with Disseminated Large Bowel Cancer. R.J. Ignoffo, M.A. Friedman, M. Gribble, and J. Hannigan. Proc. Amer. Soc. Clin. Oncol. 2, 130 (Abstract C-509) (1983).
  • Phase I Trial of the Sensitizer Misonidazole (MIS) with Intravenous Melphalan (MEL). C.N. Coleman, M.A. Friedman, R.J. Ignoffo, C. Jacobs, S.A. Leibel, J. Halsey, V.K. Hirst, M. Gribble, S.K. Carter, and T.L. Phillips. Proc. Amer. Soc. Clin. Oncol. 2, 21 (Abstract C-83) (1983).
  • Chemotherapy Infusion Devices: A Role for the Oncology Pharmacists. Proc. Amer. Soc. Hosp. Pharm. Annual Midyear Meeting, December 5-9 (Abstract S-34) (1982).
  • Current Status of the NCOG Randomized Trial of Continuous Intraarterial (IA) vs Inravenous (IV) Floxuridine in Patients with Colorectal Carcinoma Metastatic to Liver. R. Stagg, M. Friedman, B. Lewis, R. Ignoffo, J. Goodnight, C. Viele, and D. Hohn. Proc. Am. Soc. Clin. Oncol. 3, 148 (Abstract C-577) (1984).
  • Incidence and Prevention of Complications of Cyclic Hepatic Arterial Infusions of Floxuridine (FUDR): Severe Biliary Sclerosis, Gastritis, and Ulcer. D. Hohn, R. Stagg, R. Ignoffo, et al. Proc. Am. Soc. Clin. Oncol. 3, 148 (Abstract C-578) (1984).
  • A Comparison of External Pumps vs Implantable Pumps for Continuous Infusion Chemotherapy: Compliance, Complications, and Costs. R. Stagg, C. Viele, B. Lewis, R. Ignoffo, and D. Hohn. Proc. Am. Soc. Clin. Oncol. 4, 265 (Abstract C-1031) (1985).
  • Toxicities of Hepatic Arterial Chemotherapy. D.C. Hohn, W.J. Shea, B.T. Gemlo, R.J. Rayner, B.A. Lewis, R.J. Stagg, R.J. Ignoffo, et al. International Congress on Chemotherapy, August 26-28 (1985).
  • A Comparison of Two Methods of Creatinine Clearance Determination in the Cancer Patient. ASHP Midyear Meeting (#P332-R) (1986).
  • The NCOG Randomized Trial of IV vs Hepatic Arterial FudR for Colorectal Cancer Metastatic to the Liver. D. Hohn, R. Stagg, M. Friedman, and R.J. Ignoffo. Proc. Amer. Soc. Clin. Oncol. 6, 85 (Abstract 333) (1987).
  • Estimation of Creatinine Clearance in Cancer Patients with Cost Considerations. D. McCauley and R.J. Ignoffo. Proc. Amer. Soc. Clin. Oncol. 7, 67 (Abstract 257) (1988).
  • Overview of the Oncology Project Grants for Pharmacy Students Sponsored by the American Cancer Society, California Division, Pharmacists Professional Education Subcommittee. B.L. Lum, R.J. Ignoffo, D. Jamin, G. Ogawa. Amer. Assoc. Cancer Ed. (1988).